International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Arcutis Announces FDA Approval for ZORYVE (Roflumilast) Cream 0.3% for Plaque Psoriasis in Individuals Age 12 and Older

Arcutis Press Release Graphic

The United States Food and Drug Administration (FDA) announced on July 29 the approval of Arcutis’ ZORYVE™ (Roflumilast) cream 0.3% for the treatment of plaque psoriasis in individuals 12 years of age or older. ZORYVE is a once-daily, steroid-free cream approved to treat mild, moderate, and severe plaque psoriasis. ZORYVE™ has proven to provide patients with rapid clearance of plaques and reduction in itch in all affected areas of the body. This is the first and only topical phosphodiesterase-4 (PDE4) inhibitor approved to treat plaque psoriasis. The product is expected to be available mid-August.


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.



Recent Posts

Expert Insights IPC and IFPA CEO

IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives

New Councilor Headshots

Meet Our Newest Councilors

IPC and IFPA strongly advocate that early diagnosis is crucial and must be available for all individuals regardless of race, ethnicity, physical ability, culture, nationality, or geographic location blog graphic

IPC and IFPA Joint Statement on Diversity and Inclusion

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.